GALNS蛋白在肝细胞癌中的临床意义及体外生物学功能

刘泽宇; 罗袁登; 李勋; 谢传明; 张雷达

doi:10.16016/j.2097-0927.202209304

您当前的位置：

首页 >

文章列表页 >

GALNS蛋白在肝细胞癌中的临床意义及体外生物学功能

基础医学 | 更新时间：2026-01-09

- GALNS蛋白在肝细胞癌中的临床意义及体外生物学功能
- Clinical significance and in vitro biological function of GALNS protein in hepatocellular carcinoma
- 陆军军医大学学报 2022年44卷第24期页码：2514-2521
- 作者机构：
  
  400038 重庆，陆军军医大学(第三军医大学)第一附属医院全军肝胆外科研究所
- 作者简介：
  
  [张雷达，Email: zld666@aliyun.com ZHANG Leida, E-mail: zld666@aliyun.com
- 基金信息：
  
  国家自然科学基金面上项目(81972760);利益冲突所有作者声明不存在利益冲突
- DOI：10.16016/j.2097-0927.202209304
  中图分类号： R345;R730.2;R735.7
- 收稿：2022-09-30，
  
  修回：2022-10-15，
  
  纸质出版：2022-12-30
- 稿件说明：
移动端阅览
刘泽宇, 罗袁登, 李勋, 等. GALNS蛋白在肝细胞癌中的临床意义及体外生物学功能[J]. 陆军军医大学学报, 2022,44(24):2514-2521.

Zeyu LIU, Yuandeng LUO, Xun LI, et al. Clinical significance and in vitro biological function of GALNS protein in hepatocellular carcinoma[J]. Journal of Army Medical University, 2022, 44(24): 2514-2521.
刘泽宇, 罗袁登, 李勋, 等. GALNS蛋白在肝细胞癌中的临床意义及体外生物学功能[J]. 陆军军医大学学报, 2022,44(24):2514-2521. DOI： 10.16016/j.2097-0927.202209304.

Zeyu LIU, Yuandeng LUO, Xun LI, et al. Clinical significance and in vitro biological function of GALNS protein in hepatocellular carcinoma[J]. Journal of Army Medical University, 2022, 44(24): 2514-2521. DOI： 10.16016/j.2097-0927.202209304.

摘要

目的

探讨N-乙酰半乳糖胺-6-硫酸盐硫酸酯酶(N-acetylgalactosamine-6-sulfatase

GALNS)在肝细胞癌(hepatocellular carcinoma

HCC)中的临床意义及体外生物学功能。

方法

采用回顾性队列研究，对2008年1月至2014年12月间在陆军军医大学第一附属医院收治的72例肝癌患者的肿瘤组织与癌旁组织，根据免疫组织化学染色(immunohistochemical staining

IHC)结果和临床病理资料，分析GALNS在肝细胞癌中的临床意义；通过细胞迁移及增殖实验检测GALNS在肝癌细胞中的体外生物学功能。观察指标：①肝癌组织和癌旁组织的GALNS表达情况以及其与临床病理特征的关系；②GALNS对肝癌患者生存分析及危险因素分析；③下调GALNS对肝癌细胞增殖与迁移的影响。

结果

① 肝癌组织中GALNS蛋白高表达和低表达分别为32例和40例，GALNS高表达与肿瘤长径、TNM分期、肝内转移有关，差异均有统计学意义(

=20.649，14.849，5.667，

0.05)；②收集陆军军医大学第一附属医院2008年至2014年间的72例患者，GALNS蛋白低表达和高表达肝癌患者，术后1、3、5年生存率分别为87.50%、42.50%、40.00%和37.50%、12.50%、3.13%。GALNS低表达组的生存率优于高表达组，两组比较差异有统计学意义(

=9.268，

0.05)；③GALNS(

=2.502，95%

CI:

1.369~4.572，

=0.003)、远处转移(

=1.908，95%

CI:

1.018~3.573，

=0.044)、血管侵犯(

=2.361，95%

: 1.267~4.398，

=0.007)和病理分期(

=2.223，95%

: 1.185~4.171，

=0.013)是肝细胞癌的独立危险因素；④下调GALNS可显著抑制肝癌细胞增殖与转移(

0.05)。

结论

GALNS在肝癌组织中高表达，是影响肝癌患者预后的独立危险因素，下调GALNS可抑制肝癌细胞的增殖与迁移。

Abstract

Objective

To investigate the clinical significance and

in vitro

biological function of N-acetylgalactosamine-6-sulfate sulfatase (GALNS) in hepatocellular carcinoma (HCC).

Methods

A retrospective cohort study was conducted on 72 HCC patients in our hospital from January 2008 to December 2014. Their HCC tissues and para-cancerous tissues were collected and detected for GALNS expression with immunohistochemical staining. The clinical significance of GALNS in HCC was analyzed based on the results to immunohistochemical staining and clinicopathological data. The biological function of GALNS in HCC cell lines Huh7 and LM3 was detected by cell migration and proliferation assay after GALNS knockdown.

Results

① In the 72 HCC tissues

there were 32 samples with high and 40 with low expression of GALNS. Its high level was associated with tumor length

TNM stage and intrahepatic metastasis (

Chi

-square=20.649

14.849

5.667

0.05); ②The 1-

3- and 5-year survival rates of the 72 patients after surgical treatment were 87.50%

42.50% and 40.00%

respectively for those with low GALNS level

and 37.50%

12.50% and 3.13%

for those high expression level. The survival rate was significantly better in the low expression patients than those of high level (

Chi

-square=9.268

0.05); ③GALNS expression (HR=2.502

95%

=1.369- 4.572

=0.003)

distant metastasis (HR=1.908

95%

=1.018-3.573

=0.044)

vascular invasion (HR=2.361

95%

=1.267-4.398

=0.044)

=0.007) and pathological stage (HR=2.223

95%

=1.185-4.171

=0.013) were independent risk factors for HCC. ④Down-regulation of GALNS significantly inhibited the proliferation and metastasis of HCC cells (

0.05).

Conclusion

GALNS is highly expressed in liver cancer tissues and an independent risk factor for the prognosis of HCC patients. Downregulation of GALNS can inhibit the proliferation and migration of liver cancer cells.

关键词

Keywords

references

SUNG H, FERLAY J, SIEGEL R L, et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

XU X F, XING H, HAN J, et al . Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China[J ] . JAMA Surg, 2019, 154(3): 209-217. DOI: 10.1001/jamasurg.2018.4334.

QIU Z X, LI H, ZHANG Z T, et al . A pharmacogenomic landscape in human liver cancers[J ] . Cancer Cell, 2019, 36(2): 179-193. e11. DOI: 10.1016/j.ccell.2019.07.001.

BRAY F, FERLAY J, SOERJOMATARAM I, et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.

LOSIC B, CRAIG A J, VILLACORTA-MARTIN C, et al . Intratumoral heterogeneity and clonal evolution in liver cancer[J ] . Nat Commun, 2020, 11: 291. DOI: 10.1038/s41467-019-14050-z.

LI X X, LIANG L, HUANG L Y, et al . High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma[J ] . Mol Cancer, 2015, 14: 95. DOI: 10.1186/s12943-015-0356-7.

TSUCHIYA N, SAWADA Y, ENDO I, et al . Biomarkers for the early diagnosis of hepatocellular carcinoma[J ] . World J Gastroenterol, 2015, 21(37): 10573-10583. DOI: 10.3748/wjg.v21.i37.10573.

BARD-CHAPEAU E A, NGUYEN A T, RUS T A G, et al . Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model[J ] . Nat Genet, 2014, 46(1): 24-32. DOI: 10.1038/ng.2847.

LIU X R, LIANG Y J, SONG R P, et al . Long non-coding RNA NEAT1-modulated abnormal lipolysis via ATGL drives hepatocellular carcinoma proliferation[J ] . Mol Cancer, 2018, 17(1): 90. DOI: 10.1186/s12943-018-0838-5.

SUN N, LEE Y T, ZHANG R Y, et al . Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring[J ] . Nat Commun, 2020, 11(1): 4489. DOI: 10.1038/s41467-020-18311-0.

KIM S Y, AN J, LIM Y S, et al . MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma[J ] . JAMA Oncol, 2017, 3(4): 456-463. DOI: 10.1001/jamaoncol.2016.3147.

YANG P Y, LI Q J, FENG Y X, et al . TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma[J ] . Cancer Cell, 2012, 22(3): 291-303. DOI: 10.1016/j.ccr.2012.07.023.

LLOVET J M, SCHWARTZ M, MAZZAFERRO V. Resection and liver transplantation for hepatocellular carcinoma[J]. Semin Liver Dis, 2005, 25(2): 181-200. DOI: 10.1055/s-2005-871198.

XIA Y, LI J, LIU G H, et al . Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial[J ] . JAMA Oncol, 2020, 6(2): 255-263. DOI: 10.1001/jamaoncol.2019.4477.

PENG J M, LIN S H, YU M C, et al . CLIC 1 recruits PIP5K1A/C to induce cell-matrix adhesions for tumor metastasis[J ] . J Clin Invest, 2021, 131(1): 133525. DOI: 10.1172/JCI133525..

TANG B, QI G Y, SUN X Y, et al . HOXA7 plays a critical role in metastasis of liver cancer associated with activation of Snail[J ] . Mol Cancer, 2016, 15(1): 57. DOI: 10.1186/s12943-016-0540-4.

BERTOLIN J, SÁNCHEZ V, RIBERA A, et al . Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy[J ] . Nat Commun, 2021, 12(1): 5343. DOI: 10.1038/s41467-021-25697-y.

TOMATSU S, VOGLER C, MONTAÑO A M, et al . Murine model (Galns(tm(C76S)slu)) of MPS IVA with missense mutation at the active site cysteine conserved among sulfatase proteins[J ] . Mol Genet Metab, 2007, 91(3): 251-258. DOI: 10.1016/j.ymgme.2007.02.009.

RIVERA-COLÓN Y, SCHUTSKY E K, KITA A Z, et al . The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A[J ] . J Mol Biol, 2012, 423(5): 736-751. DOI: 10.1016/j.jmb.2012.08.020.

SHETH H, NAIK P, SHAH M, et al . The GALNS p. P77R variant is a probable Gujarati-Indian founder mutation causing Mucopolysaccharidosis IVA syndrome[J ] . BMC Genomics, 2022, 23(1): 458. DOI: 10.1186/s12864-022-08693-4.

TOMATSU S, MONTAÑO A M, NISHIOKA T, et al . Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A)[J ] . Hum Mutat, 2005, 26(6): 500-512. DOI: 10.1002/humu.20257.

PAN H C, XUE W K, ZHAO W J, et al . Expression and function of chondroitin 4-sulfate and chondroitin 6-sulfate in human glioma[J ] . FASEB J, 2020, 34(2): 2853-2868. DOI: 10.1096/fj.201901621RRR.

HO M L, KUO W K, CHU L J, et al . N-acetylgalactosamine-6-sulfatase (GALNS), similar to glycodelin, is a potential general biomarker for multiple malignancies[J ] . Anticancer Res, 2019, 39(11): 6317-6324. DOI: 10.21873/anticanres.13842.

JUNTTILA M R, DE SAUVAGE F J. Influence of tumour micro-environment heterogeneity on therapeutic response[J]. Nature, 2013, 501(7467): 346-354. DOI: 10.1038/nature12626.

QUAIL D F, JOYCE J A. Microenvironmental regulation of tumor progression and metastasis[J]. Nat Med, 2013, 19(11): 1423-1437. DOI: 10.1038/nm.3394.

JOYCE J A, POLLARD J W. Microenvironmental regulation of metastasis[J]. Nat Rev Cancer, 2009, 9(4): 239-252. DOI: 10.1038/nrc2618.

FERRER V P, MOURA NETO V, MENTLEIN R. Glioma infiltration and extracellular matrix: key players and modulators[J]. Glia, 2018, 66(8): 1542-1565. DOI: 10.1002/glia.23309.

FEFERMAN L, BHATTACHARYYA S, DEATON R, et al . Arylsulfatase B (N-acetylgalactosamine-4-sulfatase): potential role as a biomarker in prostate cancer[J ] . Prostate Cancer Prostatic Dis, 2013, 16(3): 277-284. DOI: 10.1038/pcan.2013.18.

VADEN R M, GLIGORICH K M, JANA R, et al . The small molecule C-6 is selectively cytotoxic against breast cancer cells and its biological action is characterized by mitochondrial defects and endoplasmic reticulum stress[J ] . Breast Cancer Res, 2014, 16(6): 472. DOI: 10.1186/s13058-014-0472-0.

KLVPPEL M, SAMAVARCHI-TEHRANI P, LIU K L, et al . C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in costello syndrome[J ] . Eur J Hum Genet, 2012, 20(8): 870-877. DOI: 10.1038/ejhg.2012.12.

GLASER J H, CONRAD H E. Chondroitin SO 4 catabolism in chick embryo chondrocytes[J ] . J Biol Chem, 1979, 254 (7): 2316-2325. DOI: 10.1016/S0021-9258(17)30223-5.

DE SOUSA JF Jr, NADER H B, DIETRICH C P. Sequential degradation of chondroitin sulfate in molluscs. Desulfation of chondroitin sulfate without prior depolymerization by a novel sulfatase from Anomalocardia brasiliana[J]. J Biol Chem, 1990, 265(33): 20150-20155. DOI: 10.1016/S0021-9258(17)30482-9.

SUAREZ-CARMONA M, LESAGE J, CATALDO D, et al . EMT and inflammation: inseparable actors of cance r progression[J ] . Mol Oncol, 2017, 11(7): 805-823. DOI: 10.1002/1878-0261.12095.

MAROZZI M, PARNIGONI A, NEGRI A, et al . Inflammation, extracellular matrix remodeling, and proteostasis in tumor microenvironment[J ] . Int J Mol Sci, 2021, 22(15): 8102. DOI: 10.3390/ijms22158102.

LIU M H, TOLG C, TURLEY E. Dissecting the dual nature of hyaluronan in the tumor microenvironment[J]. Front Immunol, 2019, 10: 947. DOI: 10.3389/fimmu.2019.00947.

BAHCECIOGLU G, BASARA G, ELLIS B W, et al . Breast cancer models: engineering the tumor microenvironment[J ] . Acta Biomater, 2020, 106: 1-21. DOI: 10.1016/j.actbio.2020.02.006.

YANG L Y, LUO Q, LU L, et al . Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response[J ] . J Hematol Oncol, 2020, 13(1): 3. DOI: 10.1186/s13045-019-0836-0.

CAI Z X, SU X P, QIU L M, et al . Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion[J ] . Mol Cancer, 2021, 20(1): 164. DOI: 10.1186/s 12943-021-01467-8.

ZHANG R, GAO X M, ZUO J L, et al . STMN 1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway[J ] . Cancer Sci, 2020, 111(2): 406-417. DOI: 10.1111/cas.14262..

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

SLC38A1通过促进谷氨酰胺摄取激活PI3K/AKT信号通路驱动肝细胞癌恶性进展

肝细胞癌临床诊治新进展：综合治疗策略的演变

程序性死亡配体-1通过抑制蛋白酪氨酸磷酸酶1B激活黏着斑激酶促进肝细胞癌进展

核表皮生长因子受体与转录因子YY1协同驱动CEMIP表达促进肝细胞癌侵袭

谷胱甘肽过氧化物酶7通过PI3K-AKT通路调控肝癌细胞增殖和衰老